Results 131 to 140 of about 2,223,665 (257)

Elucidation of sorafenib resistance mechanisms in hepatocellular carcinoma

, 2018
Includes bibliographical references (leaves 58-65).
openaire   +2 more sources

PPM1G‒MET axis sustains AKT signaling to drive Twist‐associated EMT and drug resistance in hepatocellular carcinoma

VIEW, EarlyView.
Hepatocellular carcinoma (HCC) is frequently resistant to targeted therapies. We identify protein phosphatase Mg2+/Mn2+‐dependent 1G (PPM1G) as a key phosphatase that stabilizes mesenchymal‐epithelial transition factor (MET) by inhibiting its ubiquitination, thereby sustaining protein kinase B (AKT) signaling and promoting Twist‐mediated epithelial ...
Weixun Wu, Songbin Lin, Cong Zhou, Jinwu Hu, Kun Liu, Yongfeng Xu, Zhenbin Ding, Mengting Luo, Bo Hu   +8 more
wiley   +1 more source

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma

Advanced Science
Rapid development of resistance to sorafenib and subsequent hyperprogression in patients with advanced hepatocellular carcinoma (HCC) pose significant challenges, with the underlying mechanisms still largely unknown.
Xu‐Yan Wang, Yuan Liao, Rui‐Qi Wang, Yi‐Tong Lu, Ying‐Zhe Wang, Yu‐Qi Xin, Dong‐Ming Kuang, Xiang‐Ming Lao, Junying Xu, Zhi‐Ling Zhou, Kunhua Hu   +10 more
doaj   +1 more source

NCOA5 induces sorafenib resistance in hepatocellular carcinoma by inhibiting ferroptosis

Cell Death Discovery
Abstract NCOA5 has been identified as a crucial factor in the progression of hepatocellular carcinoma (HCC). This study investigates the expression of NCOA5 in HCC, revealing its significant overexpression in tumor tissues compared to healthy liver tissues, as evidenced by analysis of the TCGA dataset and RT-qPCR in patient samples.
Shuang Gao, Lulu Fan, Huiyan Wang, Anqi Wang, Mengyao Hu, Lei Zhang, Guoping Sun   +6 more
openaire   +3 more sources

Oxidative stress‐driven metabolic reprogramming defines two subtypes of cutaneous melanoma

VIEW, EarlyView.
Cutaneous melanoma exhibits substantial molecular heterogeneity, and metabolic reprogramming may contribute to differences in tumor behavior and treatment response. In this study, we integrated multi‐omics data from SKCM cohorts to identify two metabolism‐associated subtypes with distinct oxidative stress profiles, immune microenvironments, prognostic ...
Qikun Gao, Ziyi Liu, Ying Xu
wiley   +1 more source

A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics

Andrology, EarlyView.
ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis, Lisa Schneider, Felix Bremmer, Daniel Nettersheim   +3 more
wiley   +1 more source

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukaemia patients: A multicentre real‐world study

British Journal of Haematology, EarlyView.
Summary Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS‐like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second‐generation FLT3 inhibitor gilteritinib provides better disease control compared to standard relapse therapies and was approved based on two ...
Desiree Kunadt, Sven Zukunft, Christoph Röllig, Stephan Metzelder, Andreas Burchert, Eva Wagner‐Drouet, Oliver Kriege, Christoph Schliemann, Matthias Stelljes, Julian Ronnacker, Wolfgang Bethge, Jan Frederic Weller, Björn Steffen, Gesine Bug, Khouloud Kouidri, Claudia Baldus, Lars Fransecky, Elisa Sala, Uwe Platzbecker, Klaus Metzeler, Sabine Kayser, Inken Hilgendorf, Andreas Hochhaus, Tim H. Brümmendorf, Edgar Jost, Anna Dorottya Doleschall, Thomas Schroeder, Jennifer Kaivers, Lambros Kordelas, Udo Holtick, Julia M. Unglaub, Tim Sauer, Paul Sebastian Jäger, Guido Kobbe, Elena Stauffer, Johanna Tischer, Tobias Herold, Normann Steiner, David Nachbaur, Nicolaus Kröger, Jochen J. Frietsch, Sabrina Kraus, Hermann Einsele, Mathias Hänel, Judith Schaffrath, William Krüger, Anne Brandenburg, Tobias A. W. Holderried, Laura Reinhardt, Markus Maulhardt, Christian Thiede, Martin Bornhäuser, Johannes Schetelig, Jan M. Middeke, Friedrich Stölzel, for the German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL)   +55 more
wiley   +1 more source

Renal‐vascular axis: unmasking its role in vascular endothelial growth factor‐inhibitor vascular toxicity in cancer patients

British Journal of Pharmacology, EarlyView.
Abstract Vascular toxicity is a growing concern in cancer patients receiving vascular endothelial growth factor inhibitor (VEGFi) therapy, posing a significant threat to patient prognosis. While the primary mechanism of VEGFi‐induced vascular toxicity is linked to redox‐sensitive reactions that disrupt vascular tone, leading to hypertension and ...
Grace Whelan, Karla B. Neves
wiley   +1 more source

Exosomal miR-6126 as a novel therapeutic target for overcoming resistance of anti-cancer effect in hepatocellular carcinoma

BMC Cancer
Background Hepatocellular carcinoma (HCC) stands as the sixth most prevalent cancer globally, presenting a substantial health challenge, particularly due to late-stage diagnoses that limit treatment effectiveness.
Hyemin Hwang, Jimin Kim, Tae-Hun Kim, Yeonju Han, Dayoung Choi, Sua Cho, Seunghwan Kim, Sanghee Park, Taehyun Park, Filippo Piccinini, Won Jong Rhee, Jae-Chul Pyun, Misu Lee   +12 more
doaj   +1 more source

Aptamer-coupled Doxorubicin Overcomes Sorafenib Resistance in Hepatocellular Carcinoma

, 2017
Sorafenib is a potent multi-kinase inhibitor and is the only FDA-approved first-line agent for the treatment of advanced hepatocellular carcinoma (HCC). Liver cancer stem cells (LCSCs) represent a small subset of cells within the HCC tumour mass with an ...
Zhou, Gang
core